

Gastrointestinal (GI) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



NEOADJUVANT

CCTG-CO32
(NEO-RT trial)
(opened 4/29/24)

Coord: P. Yang
PI: Dr. Zell
Accrual: 3/5

ADJUVANT

NRG-GI008/CIRCULATE
(ctDNA guided tx)
(opened 9/14/22)

Coord: A. Ballard
PI: Dr. Zell
Accrual: 5/10

INTRA-OPERATIVE

UCI 20-163
(CG-100 Intraluminal
Bypass Device)
(opened 2/27/25)

Coord: M. Nguyen
PI: Dr. Carmichael
Accrual: 2/10

MOLECULAR FAILURE

UCI 20-43
(TAS102 + irinotecan)

Coord: M. Bauk
PI: Dr. Dayyani
Accrual: 10/11



1L METASTATIC

A022101

(at least 4 months of chemo
once metastatic disease is
confirmed)

(opened 9/21/23)

Coord: A. Luna

PI: Dr. Eng
Accrual: 1/2

2L METASTATIC

ETCTN 10670

(Abemaciclib + 5-
Fluorouracil)

(opened 4/8/25)

Coord: My Nguyen

PI: Dr. Dayyani
Accrual: 2/8

3L METASTATIC

UCI 21-39

(Pembro + TATE)

(opened 8/26/21)

Coord: LM Aguilar

PI: Dr. Abi-Jaoudeh
Accrual: 30/33

UCI 24-93

(Fruquintinib)

(opened 5/28/25)

Coord: M Bauk

PI: Dr. Dayyani
Accrual: 3/7

UCI 24-142

(VET3-TGI +/-
pembrolizumab)

(opened 3/7/25)

Coord: TBD

PI: Dr. Uchio
Accrual: 0/4

Newly Diagnosed

Advanced/Metastatic

Neoadjuvant

UCI 21-191
 (SOC w/ ctDNA testing)
 (opened 6/27/25)
 Coord: A. Ballard

PI: Dr. Dayyani
 Accrual: 5/20

UCI 23-184
 Pafolacianine for
 Imaging of Peritoneal
 Carcinomatosis
 (opened 11/13/24)
 Coord: LM Aguilar
 PI: Dr. Senthil
 Accrual: 6/10

ESCC

UCI 24-77
 (I-DXd)
 Coord: TBD
 PI: Dr. Dayyani
Pending activation

Newly Diagnosed Metastatic

A022102
 (mFOLFIRINOX +/-
 Nivolumab vs. FOLFOX
 +/- Nivolumab)

Coord: M. Bauk
 PI: Dr. Dayyani
 Accrual: 8/14

EA2234
 (IV Paclitaxel + IV 5-FU + IV
 leucovorin +/- IP paclitaxel)
 (opened 8/28/25)
 Coord: LM Aguilar
 PI: Dr. Senthil
 Accrual: 0/65

UCI 21-10
 (FOLFOX + nivo +
 Bispecific antibody (anti-
 CLDN18.2 + anti-4-1BB)

Coord: M. Nguyen
 PI: Dr. Dayyani
 Accrual: 21/27

UCI 22-51
 (ASP2138 +/- 1L/2L chemo backbone)
 (opened 8/8/24)
 Coord: N. Ferrand (Gastric/GEJ); P. Yang (PDAC)
 PI: Dr. Dayyani
 Accrual: 31/35

Recurrent

UCI 16-94
 (Tirapazamine, Nivolumab)
 (opened 6/15/23)
 Coord: M Duron
 PI: Dr. Abi-Jaoudeh
 Accrual: 34/48

UCI 24-49
 (Beamion BCGC-1:
 Oral Zongertinib +
 Trastuzumab Deruxtecan or +
 Trastuzumab Emtrastine)
 (opened 10/22/24)
 Coord: M. Nguyen
 PI: Dr. Dayyani
 Accrual: 3/10

UCI 23-173
 (ICI in ARID1a Mu)
 Coord: TBD
 PI: Dr. Dayyani
Pending activation



HER-2

ETCTN-10358/DASH
(DS8201a + AZD6738)
Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 5/8

ETCTN-10495
(DS8201a + Neratinib)
(opened 3/5/25)
Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 2/7

UCI 24-49
(Beamion BCGC-1:
Oral Zongertinib +
Trastuzumab Deruxtecan)
(opened 10/22/24)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 3/10

KRAS

Open to Accrual

EGFR

Low Accruing Pending Activation/Suspended

CLDN18.2

UCI 22-51
(ASP2138)

Coord: N. Ferrand/
P. Yang
PI: Dr. Dayyani

Accrual: 31/25

UCI 23-200
(AZD0901)
(opened 7/24/24)

Coord: M. Duron
PI: Dr. Dayyani

Accrual: 5/10



UCI 23-85
(BA3182 + (EPCAM)/CD3
Antibody)

(opened 9/19/24)

Coord: H. Nguyen

PI: Dr. Valerin
Accrual: 6/8

UCI 22-26
(Androgen and
glucocorticoid receptor
antagonist)

Coord: B. Nguyen

PI: Dr. Dayyani
Accrual: 11/12

ETCTN-10579
(ZEN003694 (ZEN-3694)
+ capecitabine)

(opened 10/27/23)

Coord: P. Yang

PI: Dr. FC Lee
Accrual: 2/4

UCI 21-241
(ALK inhibitor NLV-655)

(opened 7/12/24)

Coord: A. Ballard

PI: Dr. Nagasaka
Accrual: 20/25

UCI 25-16
(ODM-212)

(opened 8/29/2025)

Coord: P. Yang

PI: Dr. Dayyani
Accrual: 0/10

UCI 25-75
(CRN09682- on SST2
expressing tumors)

Coord: TBD

PI: Dr. Dayyani
Pending activation

UCI 24-138
(Tarlatab in DLL3
Expressing Tumors +
Neuroendocrine
Neoplasms)

Coord: TBD

PI: Dr. Park
Pending activation

ETCTN-10572
(Temozolomide +
M1774)

Coord: TBD

PI: Dr. Dayyani
Pending activation



UCI 03-03

(Immunologic response analysis)

Coord: B. Sanchez
PI: Dr. Imagawa
Accrual: 336/400

UCI 23-29

(Electroacupuncture in symptom management after CRS/HIPEC)

(opened 8/8/24)

PI: Dr. Eng
Accrual: 6/10

UCI 24-05

(Rizule for Cancer- related Cognitive Impairment)

(opened 6/18/2025)

Coord: M. Bauk
PI: Dr. Chan
Accrual: 18/39

UCI 22-55

(ID GenomeSig for HomoRecomboDeficiency inPC &Mismatch RepairDeficiency in Microsatellite Instable CC)

PI: Dr. Pannunzio/Dr. Valerin
Pending activation